Suppr超能文献

基于与肾单位近端小管基因表达相似性的肾透明细胞癌生存预测。

Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron.

机构信息

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany.

出版信息

Eur Urol. 2015 Dec;68(6):1016-20. doi: 10.1016/j.eururo.2015.05.045. Epub 2015 Jun 12.

Abstract

UNLABELLED

There is evidence that molecular features support subclassification of tumours, thereby improving prediction of patient outcome. Currently, two gene expression signatures (ccA/ccB and ClearCode34) have been established to classify clear cell renal cell carcinoma (ccRCC). Because RCC arises from nephron cell types, we aimed to explore its heterogeneity on a molecular level by comparing gene expression between tumour tissue and nephron regions. Based on genes that differ in expression between nephron regions, expression data of 479 ccRCCs and 212 papillary and 66 chromophobe RCCs from The Cancer Genome Atlas were correlated to those of nephron cell types. Cancer-specific survival (CSS) of ccRCC patients was significantly associated with gene expression similarity to the proximal tubules. Subsequently, a ccRCC risk score (S3-score) was established. Survival analyses indicated that the S3-score was significantly associated with CSS considering all cases of ccRCC, as well as metastatic and nonmetastatic ccRCC. Results could be validated in an independent cohort. The S3-score significantly improved the predictive ability of the ccA/ccB and ClearCode34 signatures, and the clinicopathologic-based stage, size, grade, and necrosis score (p [chi-square] = 1.56E-04). Intratumour heterogeneity of the S3-score was observed in 6 of 10 ccRCCs. In summary, the nephron-based S3-score enables prognostic risk stratification for ccRCC. Further studies are needed to evaluate its clinical utility.

PATIENT SUMMARY

We developed a novel risk score for clear cell renal cell carcinoma to identify patients at risk of worse outcome that may improve patient care in the future.

摘要

未加标签

有证据表明分子特征支持肿瘤的细分分类,从而提高对患者预后的预测能力。目前,已经建立了两个基因表达特征(ccA/ccB 和 ClearCode34)来对透明细胞肾细胞癌(ccRCC)进行分类。由于 RCC 起源于肾单位细胞类型,我们旨在通过比较肿瘤组织和肾单位区域的基因表达来探索其分子水平上的异质性。基于在肾单位区域之间表达差异的基因,对来自癌症基因组图谱的 479 例 ccRCC 以及 212 例乳头状和 66 例嫌色细胞 RCC 的表达数据与肾单位细胞类型的表达数据进行了相关性分析。ccRCC 患者的癌症特异性生存(CSS)与与近端小管表达相似的基因表达显著相关。随后,建立了 ccRCC 风险评分(S3-评分)。生存分析表明,考虑到所有 ccRCC 病例、转移性和非转移性 ccRCC 病例,S3-评分与 CSS 显著相关。结果可在独立队列中验证。S3-评分显著提高了 ccA/ccB 和 ClearCode34 特征的预测能力,以及基于临床病理的分期、大小、分级和坏死评分(p [chi-square] = 1.56E-04)。在 10 例 ccRCC 中观察到 S3-评分的肿瘤内异质性。总之,基于肾单位的 S3-评分可对 ccRCC 进行预后风险分层。需要进一步的研究来评估其临床实用性。

患者摘要

我们开发了一种新的透明细胞肾细胞癌风险评分,以识别预后不良风险较高的患者,这可能在未来改善患者的治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验